Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of intravenous CTX-187 in healthy volunteers and patients with bacterial infection
NL-OMON61094Phase 1Recruiting
- Sponsor
- Centauri Therapeutics Limited
- Start
- May 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Countries
- 1
01
Overview
Phase 1 trial of ABX-01 in bacterial disease (2 arms), sponsored by Centauri Therapeutics Limited. Started May 2026; status: recruiting.
02
Drugs
ABX-01
03
Conditions
bacterial disease
Beyond the preview
Go deeper on NL-OMON61094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61094.